155 related articles for article (PubMed ID: 15389791)
1. Stable expression of C/EBPalpha in prostate cancer cells down-regulates metallothionein and increases zinc-induced toxicity.
Yin H; Smith M; Glass J
Prostate; 2005 Feb; 62(3):209-16. PubMed ID: 15389791
[TBL] [Abstract][Full Text] [Related]
2. In prostate cancer C/EBPalpha promotes cell growth by the loss of interactions with CDK2, CDK4, and E2F and by activation of AKT.
Yin H; Lowery M; Glass J
Prostate; 2009 Jun; 69(9):1001-16. PubMed ID: 19347879
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation and antiproliferative role of C/EBPalpha in lung cancer.
Halmos B; Huettner CS; Kocher O; Ferenczi K; Karp DD; Tenen DG
Cancer Res; 2002 Jan; 62(2):528-34. PubMed ID: 11809705
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation and growth inhibitory role of C/EBPalpha in breast cancer.
Gery S; Tanosaki S; Bose S; Bose N; Vadgama J; Koeffler HP
Clin Cancer Res; 2005 May; 11(9):3184-90. PubMed ID: 15867211
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer.
Tada Y; Brena RM; Hackanson B; Morrison C; Otterson GA; Plass C
J Natl Cancer Inst; 2006 Mar; 98(6):396-406. PubMed ID: 16537832
[TBL] [Abstract][Full Text] [Related]
6. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer.
Das S; Roth CP; Wasson LM; Vishwanatha JK
Prostate; 2007 Oct; 67(14):1550-64. PubMed ID: 17705178
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia down-regulates CCAAT/enhancer binding protein-alpha expression in breast cancer cells.
Seifeddine R; Dreiem A; Blanc E; Fulchignoni-Lataud MC; Le Frère Belda MA; Lecuru F; Mayi TH; Mazure N; Favaudon V; Massaad C; Barouki R; Massaad-Massade L
Cancer Res; 2008 Apr; 68(7):2158-65. PubMed ID: 18381421
[TBL] [Abstract][Full Text] [Related]
8. The tumour necrosis factor-alpha-mediated suppression of the CCAAT/enhancer binding protein-alpha gene transcription in hepatocytes involves inhibition of autoregulation.
Foka P; Singh NN; Salter RC; Ramji DP
Int J Biochem Cell Biol; 2009 May; 41(5):1189-97. PubMed ID: 19027873
[TBL] [Abstract][Full Text] [Related]
9. SOX9 is expressed in normal prostate basal cells and regulates androgen receptor expression in prostate cancer cells.
Wang H; McKnight NC; Zhang T; Lu ML; Balk SP; Yuan X
Cancer Res; 2007 Jan; 67(2):528-36. PubMed ID: 17234760
[TBL] [Abstract][Full Text] [Related]
10. PLZF regulates Pbx1 transcription and Pbx1-HoxC8 complex leads to androgen-independent prostate cancer proliferation.
Kikugawa T; Kinugasa Y; Shiraishi K; Nanba D; Nakashiro K; Tanji N; Yokoyama M; Higashiyama S
Prostate; 2006 Jul; 66(10):1092-9. PubMed ID: 16637071
[TBL] [Abstract][Full Text] [Related]
11. Down regulation of PSA by C/EBPalpha is associated with loss of AR expression and inhibition of PSA promoter activity in the LNCaP cell line.
Yin H; Radomska HS; Tenen DG; Glass J
BMC Cancer; 2006 Jun; 6():158. PubMed ID: 16774685
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells.
Meng AX; Jalali F; Cuddihy A; Chan N; Bindra RS; Glazer PM; Bristow RG
Radiother Oncol; 2005 Aug; 76(2):168-76. PubMed ID: 16026872
[TBL] [Abstract][Full Text] [Related]
13. The CCAAT enhancer-binding protein-alpha negatively regulates the transactivation of androgen receptor in prostate cancer cells.
Chattopadhyay S; Gong EY; Hwang M; Park E; Lee HJ; Hong CY; Choi HS; Cheong JH; Kwon HB; Lee K
Mol Endocrinol; 2006 May; 20(5):984-95. PubMed ID: 16455820
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the RSL1-dependent conditional expression system in LNCaP prostate cancer cells and development of a single vector format.
Lessard J; Aicha SB; Fournier A; Calvo E; Lavergne E; Pelletier M; Labrie C
Prostate; 2007 Jun; 67(8):808-19. PubMed ID: 17373718
[TBL] [Abstract][Full Text] [Related]
15. Diminished expression of C/EBPalpha in skin carcinomas is linked to oncogenic Ras and reexpression of C/EBPalpha in carcinoma cells inhibits proliferation.
Shim M; Powers KL; Ewing SJ; Zhu S; Smart RC
Cancer Res; 2005 Feb; 65(3):861-7. PubMed ID: 15705884
[TBL] [Abstract][Full Text] [Related]
16. Metallothioneins and resistance to cisplatin and radiation in prostate cancer.
Smith DJ; Jaggi M; Zhang W; Galich A; Du C; Sterrett SP; Smith LM; Balaji KC
Urology; 2006 Jun; 67(6):1341-7. PubMed ID: 16765200
[TBL] [Abstract][Full Text] [Related]
17. KLF5 enhances SREBP-1 action in androgen-dependent induction of fatty acid synthase in prostate cancer cells.
Lee MY; Moon JS; Park SW; Koh YK; Ahn YH; Kim KS
Biochem J; 2009 Jan; 417(1):313-22. PubMed ID: 18774944
[TBL] [Abstract][Full Text] [Related]
18. PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor.
Litvinov IV; Antony L; Dalrymple SL; Becker R; Cheng L; Isaacs JT
Prostate; 2006 Sep; 66(12):1329-38. PubMed ID: 16835890
[TBL] [Abstract][Full Text] [Related]
19. Promoter hyper-methylation of calcium binding proteins S100A6 and S100A2 in human prostate cancer.
Rehman I; Cross SS; Catto JW; Leiblich A; Mukherjee A; Azzouzi AR; Leung HY; Hamdy FC
Prostate; 2005 Dec; 65(4):322-30. PubMed ID: 16015609
[TBL] [Abstract][Full Text] [Related]
20. [Effect and possible mechanism of HnRNP E2 decoy RNA on proliferation of K562 leukemia cells].
Chen XM; Feng WL; Zhao SQ; Zeng JM; Bai WJ; Wang XZ; Huang ZG
Ai Zheng; 2006 Jul; 25(7):793-7. PubMed ID: 16831266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
